J82 Xenograft Model Overview
The J82 xenograft model originates from a human bladder carcinoma cell line derived from a poorly differentiated grade III transitional cell carcinoma of the urinary bladder. The J82 cell line was established from a 58-year-old male patient and represents an advanced urothelial cancer subtype with extensive genetic instability and an undifferentiated phenotype. As a xenograft model, J82 offers valuable insights into the biology of high-grade, muscle-invasive bladder cancer (MIBC) and is frequently utilized in studies of drug resistance, apoptosis regulation, and epigenetic dysregulation.
In vivo, J82 tumors form rapidly and exhibit aggressive growth with poor structural differentiation, making the model highly suitable for evaluating antineoplastic compounds targeting dysregulated DNA damage response (DDR) pathways, epigenetic targets, and p53-deficient tumors. The J82 model’s distinct molecular profile, including TP53 mutation, low E-cadherin expression, and chromosomal instability, closely mimics features of advanced bladder cancer seen in clinical settings. Researchers use the J82 xenograft for preclinical validation of novel therapeutic approaches, including HDAC inhibitors, DNA demethylating agents, and drugs targeting cell cycle checkpoint deregulation.
Request a Custom Quote for J82 Xenograft ModelBiological and Molecular Characteristics
The J82 cell line exhibits extensive chromosomal aberrations, a high level of aneuploidy, and global genomic instability. It carries a mutation in the TP53 tumor suppressor gene, which results in accumulation of transcriptionally inactive p53 protein, rendering cells resistant to apoptosis induced by DNA-damaging agents. The cell line shows reduced expression of RB1, altered regulation of CDKN2A/p16^INK4a, and increased cyclin E, promoting unscheduled cell cycle progression and loss of G1 checkpoint control.
J82 cells express moderate to high levels of EGFR and display increased basal activity of the AKT and ERK1/2 signaling pathways. Unlike luminal urothelial lines, J82 lacks expression of uroplakin, CK20, and other markers of terminal differentiation. The model also displays partial epithelial-to-mesenchymal transition (EMT), with co-expression of E-cadherin and vimentin, indicating phenotypic plasticity.
The table below summarizes key molecular and phenotypic traits of the J82 cell line:
| Characteristic | J82 Profile |
|---|---|
| Tissue of Origin | Human bladder, grade III transitional cell carcinoma |
| TP53 Status | Mutated (non-functional accumulation) |
| RB1 Pathway | Disrupted; low pRb expression |
| p16^INK4a Status | Altered/deregulated |
| EGFR Expression | Moderate to high |
| EMT Markers | E-cadherin+/Vimentin+ (partial EMT phenotype) |
| Differentiation Markers | Negative for CK20, uroplakin |
| Genomic Stability | High aneuploidy and chromosomal instability |
| Oncogenic Pathways | Activated AKT and ERK1/2 signaling |
| Apoptosis Regulation | p53-defective; resistant to DNA-damage-induced apoptosis |
This combination of molecular features makes J82 especially informative for testing compounds that target apoptosis resistance, cell cycle checkpoint failure, or chromatin remodeling.
In Vivo Model Development and Tumorigenicity
The J82 xenograft model demonstrates robust and reproducible tumorigenicity when injected subcutaneously into immunocompromised murine hosts, including athymic nude and NOD/SCID mice. Tumor take rates exceed 90% when 5 × 10^6 to 1 × 10^7 cells are implanted in a 1:1 Matrigel:PBS matrix. Palpable tumors typically appear within 10–14 days, with rapid volumetric expansion leading to experimental endpoints (1,200–1,500 mm³) within 3–4 weeks.
The tumors exhibit aggressive local expansion but remain confined to the subcutaneous compartment under standard conditions. However, in orthotopic implantation models—achieved by intravesical instillation or direct bladder wall injection—J82 cells demonstrate bladder wall invasion, stromal penetration, and occasionally, lymphovascular involvement. These properties enable the model to be adapted for studies requiring more clinically relevant microenvironments or investigations into locoregional spread.
J82 xenografts are suitable for longitudinal assessment using caliper measurements or advanced imaging modalities such as MRI or bioluminescent tracking (if genetically labeled). Tumors are highly cellular and vascularized, permitting pharmacokinetic and pharmacodynamic profiling of drug accumulation, metabolism, and target engagement.
Request a Custom Quote for J82 Xenograft ModelHistopathology and Immunohistochemical Profile
Tumors derived from J82 xenografts are characterized by poorly differentiated sheets of large, pleomorphic cells with high nuclear-to-cytoplasmic ratios, vesicular nuclei, and frequent abnormal mitoses. There is minimal glandular or papillary structure, and necrosis is common in tumors exceeding 1,000 mm³. Histological features closely resemble those of high-grade invasive urothelial carcinomas with sarcomatoid dedifferentiation.
Immunohistochemical staining reveals elevated nuclear Ki-67 expression (>70% labeling index), consistent with rapid proliferation. EGFR is strongly expressed at the membrane, while phospho-AKT and phospho-ERK1/2 are present in cytoplasmic compartments, confirming activation of these oncogenic signaling pathways. J82 tumors display heterogeneous E-cadherin staining and co-localization with vimentin, supporting the partial EMT phenotype.
Additional IHC features include low or absent uroplakin, negative CK20, and focal expression of CD44, a cancer stem cell-associated surface marker. Tumor vasculature is prominent, with high CD31 positivity, enabling efficient drug delivery and diffusion studies. The absence of p53 nuclear staining supports the known TP53 mutation and functional loss.
Preclinical Applications and Drug Response
The J82 xenograft model is widely employed in translational research to evaluate therapies targeting DNA repair mechanisms, apoptotic regulation, and chromatin remodeling. Due to its p53 mutation and RB1 pathway disruption, J82 is particularly resistant to conventional genotoxic chemotherapies, such as cisplatin or mitomycin C, and serves as an excellent model for studying drug resistance and compensatory survival mechanisms.
This model is also commonly used in the evaluation of HDAC inhibitors, DNMT inhibitors, and other epigenetic agents, given its deregulated chromatin structure and histone modification profile. Inhibitors of PI3K, AKT, and MEK have demonstrated partial efficacy, although responses are variable and often short-lived, reflecting tumor plasticity and pathway redundancy. Such characteristics make J82 valuable in combination therapy studies and mechanistic dissection of adaptive resistance.
Additionally, the model is informative for investigations into EMT regulation, cell cycle checkpoint inhibition, and apoptosis-restoring agents such as BH3 mimetics. The aggressive, p53-null biology of J82 provides a clinically relevant context for identifying therapies effective against non-responsive bladder tumors.
Request This Model
To request the J82 xenograft model or inquire about orthotopic implantation, resistance profiling, or custom drug efficacy studies, please use the request form below. Our team will provide consultation on study design, cost structure, and model-specific customization for your research objectives.
Request a Custom Quote for J82 Xenograft Model